Financial reports
ARS
2023 FY
Annual report to shareholders
6 Mar 24
10-K
2023 FY
Annual report
29 Feb 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
12 May 23
ARS
2022 FY
Annual report to shareholders
22 Mar 23
10-K
2022 FY
Annual report
9 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
Current reports
8-K
Akili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
29 Feb 24
8-K
Japanese Product Now Under Review for Nationwide Marketing Approval
26 Feb 24
8-K
Akili Announces Release Date for Fourth Quarter and Full Year 2023
21 Feb 24
8-K
Departure of Directors or Certain Officers
5 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
20 Dec 23
8-K
EndeavorRx®, World’s First and Only Prescription Video Game Treatment, Secures FDA Label Expansion for Pediatric ADHD Patients Aged 13-17
18 Dec 23
8-K
Akili Reports Third Quarter 2023 Financial Results and Provides Business Update
9 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
27 Oct 23
8-K
Akili Announces Leadership Transition
6 Oct 23
8-K
Akili Announces Business Transformation, Focusing on Non-prescription Model
13 Sep 23
Registration and prospectus
S-8
Registration of securities for employees
29 Feb 24
POS AM
Prospectus update (post-effective amendment)
27 Sep 23
424B3
Prospectus supplement
13 Sep 23
POS AM
Prospectus update (post-effective amendment)
5 Sep 23
424B3
Prospectus supplement
10 Aug 23
424B3
Prospectus supplement
10 Aug 23
424B3
Prospectus supplement
7 Jun 23
424B3
Prospectus supplement
12 May 23
424B3
Prospectus supplement
11 May 23
424B3
Prospectus supplement
4 May 23
Other
EFFECT
Notice of effectiveness
29 Sep 23
EFFECT
Notice of effectiveness
27 Mar 23
EFFECT
Notice of effectiveness
18 Oct 22
CORRESP
Correspondence with SEC
13 Oct 22
CORRESP
Correspondence with SEC
30 Sep 22
UPLOAD
Letter from SEC
27 Sep 22
CORRESP
Correspondence with SEC
12 Sep 22
UPLOAD
Letter from SEC
6 Sep 22
SEC STAFF
SEC staff action: Order
25 Jul 22
EFFECT
Notice of effectiveness
22 Jul 22
Ownership
4
Jacqueline Studer
12 Mar 24
4
Walter Edward Martucci II
12 Mar 24
4
Matthew Franklin
12 Mar 24
4
John Spinale
23 Feb 24
3
John Spinale
23 Feb 24
SC 13G/A
Cowen Aaron
13 Feb 24
SC 13G
Neuberger Berman Group LLC
12 Feb 24
SC 13G/A
BAILLIE GIFFORD & CO
29 Jan 24
4
Jacqueline Studer
8 Dec 23
4
Santosh Shanbhag
8 Dec 23